← Back to Search

Other

Treatment B: PF-07940367 Product I for Healthy Subjects

Phase 1
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BMI of 16-32 kg/m2; and a total body weight >50 kg (110 lb).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to 336 hours after pf-07940367 dose
Awards & highlights

Study Summary

This trial aims to compare two versions of a medication called PF-07940367 to see how they are absorbed into the bloodstream. They are looking for healthy men and women aged 18 or older to

Who is the study for?
This study is for healthy adults aged 18 or older. Participants will be involved in the trial for approximately 112 days, which includes a 5-day onsite stay and additional onsite and remote visits.Check my eligibility
What is being tested?
The trial is testing two different finished products of a medication called PF-07940367 to see how they are absorbed into the bloodstream when taken orally.See study design
What are the potential side effects?
Since this trial involves healthy volunteers and specific side effects are not listed, it's important to note that any medication can cause reactions, which will be closely monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 16 and 32, and I weigh more than 110 pounds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to 336 hours after pf-07940367 dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to 336 hours after pf-07940367 dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 products
Secondary outcome measures
Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of PF-07940367 for two PF-07940367 products
Maximum Observed Whole Blood Concentration (Cmax) of PF-07940367 for two PF-07940367 products
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment B: PF-07940367 Product IExperimental Treatment1 Intervention
tablet by mouth
Group II: Treatment A: PF-07940367 Product IIExperimental Treatment1 Intervention
tablet by mouth

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,915,966 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,476 Previous Clinical Trials
8,092,161 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for potential participants to enroll in this trial?

"Based on the information available on clinicaltrials.gov, this particular study is not actively seeking participants. However, it was initially posted on January 15th, 2024 and last updated on December 19th, 2023. It's worth noting that there are currently a total of 747 ongoing clinical trials actively recruiting patients at this time."

Answered by AI

What are the potential risks associated with Treatment A: PF-07940367 Product II for individuals receiving medical care?

"Based on the assessment by our team at Power, Treatment A: PF-07940367 Product II has been assigned a safety rating of 1. This is because it is currently in Phase 1 of the trial, indicating that there is limited available data supporting both its safety and efficacy."

Answered by AI

Who else is applying?

What site did they apply to?
Anaheim Clinical Trials, LLC
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults
2024. "A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06190561.
~26 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top